Completed PHASE1 INTERVENTIONAL 2-arm NCT02578082

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208

Sponsor: Mylan Inc.

Interventions TD-4208

Updated 11 times since 2017 Last updated: Feb 22, 2022 Started: Dec 31, 2015 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02578082, this PHASE1 trial focuses on Renal Impairment and remains completed. Sponsored by Mylan Inc., it has been updated 11 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1
Jun 2021 — Mar 2022 [monthly]

Completed PHASE1
Jan 2021 — Jun 2021 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Dec 2019 — Jan 2021 [monthly]

Completed PHASE1
Oct 2018 — Dec 2019 [monthly]

Completed PHASE1
Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Mar 2018 — Jun 2018 [monthly]

Completed PHASE1

Phase: PHASE1_PHASE2 → PHASE1
Feb 2017 — Mar 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mylan Inc.
Theravance Biopharma

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orlando, United States